NEW YORK (GenomeWeb News) – Atossa Genetics today announced a manufacturing agreement with HLB for its Mammary Aspirate Specimen Cytology Test for field testing before commercial launch.
Financial terms of the deal were not disclosed.
MASCT is a medical device and method for collecting, shipping, and clinically analyzing nipple aspirate fluid, which contains cells and molecular diagnostic markers that can be used to detect breast cancer as well as cellular changes that may be precursors to breast cancer. The system has been cleared by the US Food and Drug Administration.
The Seattle-based molecular diagnostics company said that it plans to launch MASCT in the Pacific Northwest this year with a wider release in 2012.